Hanssen et al. have shown alteration of the kynurenine pathway in MASLD patients, favoring inflammation and fibrosis through regulation by inflammation markers such as IFN, IL6, LPS [56]. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.